AUXL up +0.80% percent Today $AUXL High is at 33.16 and the Low 32.74 with current volume of 239,185.
Recent News posted below.
Auxilium Pharmaceuticals AUXL other info.
http://investorshangout.com/Auxilium-Pharmace...UXL-53427/
AUXL Auxilium Pharmaceuticals Recent Headline News
Waiting period over for Endo/Auxilium merger
Seeking Alpha - at Seeking Alpha - 1 hr 32 mins ago
ENDP: 69.50 (-0.01), AUXL: 33.01 (+0.32)
Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed Acquisition of Auxilium Pharmaceuticals
PR Newswire - Wed Nov 19, 6:30AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"
in connection with Endo's proposed acquisition of Auxilium was terminated by the United States Federal Trade Commission on November 18, 2014. Endo now expects the deal to close in the first quarter of 2015, subject to pending customary closing conditions.
ENDP: 69.50 (-0.01), ENL.TO: 78.60 (-0.99), AUXL: 33.01 (+0.32)
Shares of AUXL Up 61.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 18, 9:09AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 3 months, Auxilium Pharmaceuticals has returned 61.43% as of today's recent price of $32.60.
AUXL: 33.01 (+0.32)
Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer
Business Wire - Tue Nov 18, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of James E. Fickenscher to the position of Senior Vice President, Chief Financial Officer. Mr. Fickenscher has a diversified corporate background including more than 25 years of experience in the pharmaceutical industry.
AUXL: 33.01 (+0.32), ATRS: 2.23 (-0.03)
Auxilium Pharmaceuticals Earnings Review: 18 Days after Announcement Shares Up 0.9% (AUXL)
Comtex SmarTrend(R) - Mon Nov 17, 1:26PM CST
When Auxilium Pharmaceuticals (NASDAQ:AUXL) reported earnings two weeks ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.12 on sales of $100.9 million. The company actually reported EPS of $0.27 on sales of $109.6 million, beating EPS estimates by $0.15 and beating revenue estimates by $8.8 million. Shares of Auxilium Pharmaceuticals have climbed from $31.88 to $32.17, representing a gain of 0.9% since the company reported earnings 18 days ago.
AUXL: 33.01 (+0.32)
NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:50AM CST
NPS Pharma (NPSP) reported a loss of 2 cents per share in the third quarter of 2014, wider than the year-ago loss of 1 cent per share.
AUXL: 33.01 (+0.32), NPSP: 31.42 (+0.74), AMGN: 162.63 (+0.39), BIOD: 1.58 (-0.03)
Regulus Slumps: RGLS Falls 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:53AM CST
Regulus has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past 24 hours
ACRX: 6.70 (-0.13), AUXL: 33.01 (+0.32), ADHD: 3.25 (+0.01), RGLS: 16.72 (-1.40)
ArQule (ARQL) Catches Eye: Stock Jumps 10.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:30AM CST
ArQule Inc. (ARQL) was a big mover last session, as the company saw its shares rise over 10% on the day.
ACRX: 6.70 (-0.13), AUXL: 33.01 (+0.32), ADHD: 3.25 (+0.01), ARQL: 1.26 (-0.02)
61.9% Return Seen to Date on SmarTrend Auxilium Pharmaceuticals Call (AUXL)
Comtex SmarTrend(R) - Mon Nov 10, 4:47PM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 2 months, Auxilium Pharmaceuticals has returned 61.92% as of today's recent price of $32.70.
AUXL: 33.01 (+0.32)
Avanir Faces Regulatory Setback, AVP-825 Could Be Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:40PM CST
Avanir Pharmaceuticals, Inc. (AVNR) received a disappointing preliminary feedback from the FDA regarding its new drug application for AVP-825.
LCI: 46.87 (+0.17), AVNR: 13.84 (+0.14), AUXL: 33.01 (+0.32), GSK: 46.29 (+0.01)
Intercept Pharmaceuticals' Shares Crash on FLINT Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:03PM CST
Shares of Intercept Pharmaceuticals, Inc. (ICPT) plunged 30.1% following the publication of additional results from the FLINT trial on its lead candidate, obeticholic acid (OCA) in The Lancet.
CYTK: 4.18 (+0.02), BIIB: 303.90 (-1.66), AUXL: 33.01 (+0.32), ICPT: 156.62 (-5.88)
Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 213.19 (-0.18), VRX: 141.85 (-0.09), AUXL: 33.01 (+0.32), SLXP: 105.46 (+0.07)
Auxilium Pharmaceuticals Earnings Hindsight: Up 2.7% in Last 11 Days (AUXL)
Comtex SmarTrend(R) - Mon Nov 10, 12:17PM CST
A week ago on October 30th, 2014 Auxilium Pharmaceuticals (NASDAQ:AUXL) reported earnings and analysts, on average, expected earnings of $0.12 on sales of $100.9 million. The company actually reported EPS of $0.27 on sales of $109.6 million, beating EPS estimates by $0.15 and beating revenue estimates by $8.8 million. Shares of Auxilium Pharmaceuticals have climbed from $31.88 to $32.75, representing a gain of 2.7% since the company reported earnings 11 days ago.
AUXL: 33.01 (+0.32)
Nektar Therapeutics Beats on Q3 Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 11:20AM CST
Nektar (NKTR) reported third-quarter 2014 earnings of 53 cents per share, beating the Zacks Consensus Estimate of 39 cents.
BAX: 72.37 (-0.21), AUXL: 33.01 (+0.32), AZN: 75.34 (+1.36), NKTR: 13.93 (-0.16)
Update: Auxilium Pharmaceuticals Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:28PM CST
ENDP: 69.50 (-0.01), AUXL: 33.01 (+0.32)
Salix Q3 Earnings Marred by Inventory Issues, Cuts View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 10:09AM CST
Salix's (SLXP) Audit Committee has appointed outside counsel to probe the inventory issues.
AGN: 213.19 (-0.18), BIIB: 303.90 (-1.66), AUXL: 33.01 (+0.32), SLXP: 105.46 (+0.07)
Endocyte, Inc. (ECYT) in Focus: Stock Surges 18% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:18AM CST
Endocyte, Inc. (ECYT) was a big mover last session, as the company saw its shares rise 18% on the day.
ECYT: 6.47 (+0.09), AUXL: 33.01 (+0.32), ADHD: 3.25 (+0.01), BIOD: 1.58 (-0.03)
VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:45PM CST
VIVUS Inc.'s (VVUS) third-quarter 2014 loss of 11 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 21 cents.
AUXL: 33.01 (+0.32), VVUS: 3.11 (+0.07), AMAG: 35.51 (+0.17), SNY: 48.26 (-0.10)
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 12:20PM CST
Ironwood reported a loss of 30 cents per share in the third quarter of 2014, narrower than the year-ago loss of 51 cents
ACT: 268.22 (-1.38), VRX: 141.85 (-0.09), IRWD: 13.55 (+0.15), AUXL: 33.01 (+0.32)
Recent News posted below.
Auxilium Pharmaceuticals AUXL other info.
http://investorshangout.com/Auxilium-Pharmace...UXL-53427/
AUXL Auxilium Pharmaceuticals Recent Headline News
Waiting period over for Endo/Auxilium merger
Seeking Alpha - at Seeking Alpha - 1 hr 32 mins ago
ENDP: 69.50 (-0.01), AUXL: 33.01 (+0.32)
Endo Announces Early Termination of HSR Act Waiting Period in Connection with its Proposed Acquisition of Auxilium Pharmaceuticals
PR Newswire - Wed Nov 19, 6:30AM CST
Endo International plc (NASDAQ: ENDP) (TSX: ENL) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"
in connection with Endo's proposed acquisition of Auxilium was terminated by the United States Federal Trade Commission on November 18, 2014. Endo now expects the deal to close in the first quarter of 2015, subject to pending customary closing conditions. ENDP: 69.50 (-0.01), ENL.TO: 78.60 (-0.99), AUXL: 33.01 (+0.32)
Shares of AUXL Up 61.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Nov 18, 9:09AM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 3 months, Auxilium Pharmaceuticals has returned 61.43% as of today's recent price of $32.60.
AUXL: 33.01 (+0.32)
Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer
Business Wire - Tue Nov 18, 6:00AM CST
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of James E. Fickenscher to the position of Senior Vice President, Chief Financial Officer. Mr. Fickenscher has a diversified corporate background including more than 25 years of experience in the pharmaceutical industry.
AUXL: 33.01 (+0.32), ATRS: 2.23 (-0.03)
Auxilium Pharmaceuticals Earnings Review: 18 Days after Announcement Shares Up 0.9% (AUXL)
Comtex SmarTrend(R) - Mon Nov 17, 1:26PM CST
When Auxilium Pharmaceuticals (NASDAQ:AUXL) reported earnings two weeks ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.12 on sales of $100.9 million. The company actually reported EPS of $0.27 on sales of $109.6 million, beating EPS estimates by $0.15 and beating revenue estimates by $8.8 million. Shares of Auxilium Pharmaceuticals have climbed from $31.88 to $32.17, representing a gain of 0.9% since the company reported earnings 18 days ago.
AUXL: 33.01 (+0.32)
NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 10:50AM CST
NPS Pharma (NPSP) reported a loss of 2 cents per share in the third quarter of 2014, wider than the year-ago loss of 1 cent per share.
AUXL: 33.01 (+0.32), NPSP: 31.42 (+0.74), AMGN: 162.63 (+0.39), BIOD: 1.58 (-0.03)
Regulus Slumps: RGLS Falls 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:53AM CST
Regulus has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past 24 hours
ACRX: 6.70 (-0.13), AUXL: 33.01 (+0.32), ADHD: 3.25 (+0.01), RGLS: 16.72 (-1.40)
ArQule (ARQL) Catches Eye: Stock Jumps 10.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:30AM CST
ArQule Inc. (ARQL) was a big mover last session, as the company saw its shares rise over 10% on the day.
ACRX: 6.70 (-0.13), AUXL: 33.01 (+0.32), ADHD: 3.25 (+0.01), ARQL: 1.26 (-0.02)
61.9% Return Seen to Date on SmarTrend Auxilium Pharmaceuticals Call (AUXL)
Comtex SmarTrend(R) - Mon Nov 10, 4:47PM CST
SmarTrend identified an Uptrend for Auxilium Pharmaceuticals (NASDAQ:AUXL) on September 4th, 2014 at $20.20. In approximately 2 months, Auxilium Pharmaceuticals has returned 61.92% as of today's recent price of $32.70.
AUXL: 33.01 (+0.32)
Avanir Faces Regulatory Setback, AVP-825 Could Be Delayed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:40PM CST
Avanir Pharmaceuticals, Inc. (AVNR) received a disappointing preliminary feedback from the FDA regarding its new drug application for AVP-825.
LCI: 46.87 (+0.17), AVNR: 13.84 (+0.14), AUXL: 33.01 (+0.32), GSK: 46.29 (+0.01)
Intercept Pharmaceuticals' Shares Crash on FLINT Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:03PM CST
Shares of Intercept Pharmaceuticals, Inc. (ICPT) plunged 30.1% following the publication of additional results from the FLINT trial on its lead candidate, obeticholic acid (OCA) in The Lancet.
CYTK: 4.18 (+0.02), BIIB: 303.90 (-1.66), AUXL: 33.01 (+0.32), ICPT: 156.62 (-5.88)
Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 213.19 (-0.18), VRX: 141.85 (-0.09), AUXL: 33.01 (+0.32), SLXP: 105.46 (+0.07)
Auxilium Pharmaceuticals Earnings Hindsight: Up 2.7% in Last 11 Days (AUXL)
Comtex SmarTrend(R) - Mon Nov 10, 12:17PM CST
A week ago on October 30th, 2014 Auxilium Pharmaceuticals (NASDAQ:AUXL) reported earnings and analysts, on average, expected earnings of $0.12 on sales of $100.9 million. The company actually reported EPS of $0.27 on sales of $109.6 million, beating EPS estimates by $0.15 and beating revenue estimates by $8.8 million. Shares of Auxilium Pharmaceuticals have climbed from $31.88 to $32.75, representing a gain of 2.7% since the company reported earnings 11 days ago.
AUXL: 33.01 (+0.32)
Nektar Therapeutics Beats on Q3 Earnings and Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 11:20AM CST
Nektar (NKTR) reported third-quarter 2014 earnings of 53 cents per share, beating the Zacks Consensus Estimate of 39 cents.
BAX: 72.37 (-0.21), AUXL: 33.01 (+0.32), AZN: 75.34 (+1.36), NKTR: 13.93 (-0.16)
Update: Auxilium Pharmaceuticals Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Sat Nov 08, 4:28PM CST
ENDP: 69.50 (-0.01), AUXL: 33.01 (+0.32)
Salix Q3 Earnings Marred by Inventory Issues, Cuts View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 10:09AM CST
Salix's (SLXP) Audit Committee has appointed outside counsel to probe the inventory issues.
AGN: 213.19 (-0.18), BIIB: 303.90 (-1.66), AUXL: 33.01 (+0.32), SLXP: 105.46 (+0.07)
Endocyte, Inc. (ECYT) in Focus: Stock Surges 18% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:18AM CST
Endocyte, Inc. (ECYT) was a big mover last session, as the company saw its shares rise 18% on the day.
ECYT: 6.47 (+0.09), AUXL: 33.01 (+0.32), ADHD: 3.25 (+0.01), BIOD: 1.58 (-0.03)
VIVUS Posts Narrower-than-Expected Q3 Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:45PM CST
VIVUS Inc.'s (VVUS) third-quarter 2014 loss of 11 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 21 cents.
AUXL: 33.01 (+0.32), VVUS: 3.11 (+0.07), AMAG: 35.51 (+0.17), SNY: 48.26 (-0.10)
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 12:20PM CST
Ironwood reported a loss of 30 cents per share in the third quarter of 2014, narrower than the year-ago loss of 51 cents
ACT: 268.22 (-1.38), VRX: 141.85 (-0.09), IRWD: 13.55 (+0.15), AUXL: 33.01 (+0.32)
